Notice regarding Differences in the Non-consolidated Financial Results between the Fiscal Year Ended March 31, 2023 and the Previous Fiscal Year
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara) today announced that there were differences in the non-consolidated financial results (Japanese standard) between the fiscal year (FY) ended March 2023 (April 1, 2022 to March 31, 2023) and previous FY.
- Differences in the full-year non-consolidated financial results between the FY ended March 2023 and the previous FY
(Millions of yen, except basic earnings per share)
for the year
(FY ended March 2022)
357,023 119,899 121,057 94,594 190.51 Actual Results(B)
(FY ended March 2023)
441,242 152,004 150,755 117,190 239.96 Change（B－A） 84,219 32,105 29,699 22,596 - Change（％） 23.6 26.8 24.5 23.9 -
- Reasons for the differences
Because of the growth in sales of main products such as “Opdivo Intravenous Infusion” for malignant tumors, and “Forxiga Tablets” for diabetes, chronic heart failure and chronic kidney disease, etc., as well as an increase in royalty revenue, there were differences in the full-year non-consolidated financial results between the FY ended March 31, 2023 and the previous FY.